EMERYVILLE, Calif., JANUARY 7, 2016 – Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and CEO, will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.
Dr. Allen’s presentation will take place on Tuesday, January 12, 2016 at 4:30 p.m. Pacific Time in the “Elizabethan D” room at the Westin St. Francis.
About Gritstone Oncology
Gritstone Oncology is a privately-held cancer immunotherapy company developing next- generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. Gritstone Oncology is headquartered in the San Francisco Bay Area with certain key functions located in Cambridge, MA. The company launched in October 2015 with a Series A financing of $102 million from leading, blue-chip biotechnology investors, including Versant Ventures, The Column Group and Clarus Ventures. More information can be found at www.gritstoneoncology.com.